Japan's PMDA looks to the future as it balances access and safety
This article was originally published in Scrip
Since it was set up in April 2004, bringing together drug and medical device regulatory functions then split between various government bodies, the PMDA has not always elicited the kindest of comments from applicants. Frustrations have sometimes been expressed at review times, procedures and difficulties finding slots for consultations. But things have improved markedly over the last few years and the tone of comments one now hears from industry has become much more positive.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.